AAN 2023 oral presentation: Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial

This AAN 2023 oral presentation focused on ataluren use for the treatment of nonsense mutation Duchene muscular dystrophy (nmDMD) patients. The symposium detailed the efficacy and safety profile of ataluren in Study 041

Appreciate the trial design and patient characteristics in Study 041
Explore the efficacy of ataluren in nmDMD across multiple motor endpoints
Understand the safety profile of ataluren in nmDMD

▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at pharmacovigilance@ptcbio.com.

Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.

This oral presentation was developed and funded by PTC Therapeutics for AAN 2023.

Register now to unlock the content

Already registered?
If not, register below

Registration

Firstname *

Surname *

Hospital *

Work email *

Specialty *

Country *

This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

*

I confirm that I am a licensed healthcare professional and would like to access this Website

*

I understand that PTC will process my personal data, including contact details, for the purposes of providing me access to this Website

I want PTC to provide, by email, updates about new content available to view on MEDhub
PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

AAN 2023 oral presentation: Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial

Authenticating...

COMING SOON